Cargando…
P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430340/ http://dx.doi.org/10.1097/01.HS9.0000847216.85071.f3 |
| _version_ | 1784779740586967040 |
|---|---|
| author | Herrera, A. F. Lavie, D. Johnson, N. A. Avigdor, A. Borchmann, P. Andreadis, C. Bazargan, A. Gregory, G. Keane, C. Inna, T. Vucinic, V. Zinzani, P. L. Zhang, H. Pillai, P. Marinello, P. Timmerman, J. |
| author_facet | Herrera, A. F. Lavie, D. Johnson, N. A. Avigdor, A. Borchmann, P. Andreadis, C. Bazargan, A. Gregory, G. Keane, C. Inna, T. Vucinic, V. Zinzani, P. L. Zhang, H. Pillai, P. Marinello, P. Timmerman, J. |
| author_sort | Herrera, A. F. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430340 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94303402022-08-31 P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY Herrera, A. F. Lavie, D. Johnson, N. A. Avigdor, A. Borchmann, P. Andreadis, C. Bazargan, A. Gregory, G. Keane, C. Inna, T. Vucinic, V. Zinzani, P. L. Zhang, H. Pillai, P. Marinello, P. Timmerman, J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430340/ http://dx.doi.org/10.1097/01.HS9.0000847216.85071.f3 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Herrera, A. F. Lavie, D. Johnson, N. A. Avigdor, A. Borchmann, P. Andreadis, C. Bazargan, A. Gregory, G. Keane, C. Inna, T. Vucinic, V. Zinzani, P. L. Zhang, H. Pillai, P. Marinello, P. Timmerman, J. P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY |
| title | P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_full | P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_fullStr | P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_full_unstemmed | P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_short | P1087: FAVEZELIMAB (ANTI–LAG-3) AND PEMBROLIZUMAB CO-BLOCKADE IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA WHO PROGRESSED AFTER ANTI–PD-1 THERAPY: AN OPEN-LABEL PHASE 1/2 STUDY |
| title_sort | p1087: favezelimab (anti–lag-3) and pembrolizumab co-blockade in patients with relapsed or refractory classical hodgkin lymphoma who progressed after anti–pd-1 therapy: an open-label phase 1/2 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430340/ http://dx.doi.org/10.1097/01.HS9.0000847216.85071.f3 |
| work_keys_str_mv | AT herreraaf p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT lavied p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT johnsonna p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT avigdora p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT borchmannp p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT andreadisc p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT bazargana p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT gregoryg p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT keanec p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT innat p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT vucinicv p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT zinzanipl p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT zhangh p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT pillaip p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT marinellop p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study AT timmermanj p1087favezelimabantilag3andpembrolizumabcoblockadeinpatientswithrelapsedorrefractoryclassicalhodgkinlymphomawhoprogressedafterantipd1therapyanopenlabelphase12study |